MRC Technology and EMBLEM Collaborate to Streamline Drug Development
News Apr 15, 2013
MRC Technology has announced that it has entered into a strategic collaboration with EMBL Enterprise Management Technology Transfer GmbH (EMBLEM), the exclusive technology transfer partner of the European Molecular Biology Laboratory (EMBL).
The initiative will focus on identification of novel druggable targets in the field of small molecules and antibodies, and collaborating to fast track those targets through drug discovery to create potent and selective novel therapeutics.
The agreement brings together EMBLEM’s experience in supporting academics in one of the world’s leading locations for scientific research, with MRC Technology’s dedicated expertise in translating novel biology targets into lead stage therapeutic assets.
Dr Dave Tapolczay, MRC Technology’s CEO, commented, “Heidelberg is a world centre for academic research and we are delighted to be collaborating with EMBLEM, and researchers from the EMBL Chemical Biology group. The skills of the two organizations are highly complementary, and the initiative further strengthens MRC Technology’s academic drug development and commercialization network - ultimately working towards improving the rate at which academic research is translated into new medicines.”
EMBLEM’s Managing Director, Dr. Gábor Lamm, said “We work closely with a network of partners to develop technologies to a sufficient level of maturity such that they can be transferred to industry. We look forward to working with MRC Technology to identify projects for collaborative screening and further development.”
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE